Skip to main content
SpringerLink
Log in
Book cover

Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents pp 565–577Cite as

Clinically Significant Interactions with Anti-addiction Agents

  • Chapter
  • First Online:

  • 2633 Accesses

Abstract

Anti-addiction agents are important psychopharmacological agents used to treat addiction to opioids (illicit and licit), alcohol and nicotine. The goal of treatment is to eliminate further use of the addicted drug by either preventing addicted drug reward or managing withdrawal symptoms experienced when the addicted drug is no longer used. Treatment success relies on adequate plasma and brain concentrations to produce the required pharmacodynamic response without toxic adverse effects. In this chapter, we describe clinically significant drug-drug interactions caused by changes in pharmacokinetics (induction or inhibition of metabolism) and pharmacodynamics (inhibited, additive or synergistic activity at the drug target) of the anti-addiction agents that alter treatment success, cause harmful effects and/or have led to recommendations from regulatory bodies regarding dosage adjustments or additional monitoring for patient safety. Clinicians need to be aware of the potential for these drug-drug interactions and prescribe and monitor patients for safety and efficacy as needed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Romach MK, Piafsky KM, Abel JG, Khouw V, Sellers EM (1981) Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma. Clin Pharmacol Ther 29:211–217

    Article  CAS  PubMed  Google Scholar 

  2. Gelston EA et al (2012) Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. Br J Clin Pharmacol 73:786–794

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. McCance-Katz EF, Sullivan LE, Nallani S (2010) Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 19:4–16

    Article  PubMed  PubMed Central  Google Scholar 

  4. Saber-Tehrani AS, Bruce RD, Altice FL (2011) Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am J Drug Alcohol Abuse 37:1–11

    Article  PubMed  Google Scholar 

  5. Moody DE (2013) Metabolic and toxicological considerations of the opioid replacement therapy drugs: methadone and buprenorphine. Expert Opin Drug Metab Toxicol 9:675–697

    Article  CAS  PubMed  Google Scholar 

  6. Garrett ER, Chandran VR (1985) Pharmacokinetics of morphine and its surrogates VI: bioanalysis, solvolysis kinetics, solubility, pK’a values, and protein binding of buprenorphine. J Pharm Sci 74:515–524

    Article  CAS  PubMed  Google Scholar 

  7. Saivin S et al (1998) Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 35:331–345

    Article  CAS  PubMed  Google Scholar 

  8. Mason BJ et al (2002) A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 27:596–606

    Article  CAS  PubMed  Google Scholar 

  9. Eneanya DI, Bianchine JR, Duran DO, Andresen BD (1981) The actions and metabolic fate of disulfiram. Annu Rev Pharmacol Toxicol 21:575–596

    Article  CAS  PubMed  Google Scholar 

  10. Johansson B (1990) Plasma protein binding of disulfiram and its metabolite diethylthiocarbamic acid methyl ester. J Pharm Pharmacol 42:806–807

    Article  CAS  PubMed  Google Scholar 

  11. Chick J (1999) Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 20:427–435

    Article  CAS  PubMed  Google Scholar 

  12. Barth KS, Malcolm RJ (2010) Disulfiram: an old therapeutic with new applications. CNS Neurol Disord Drug Targets 9:5–12

    Article  CAS  PubMed  Google Scholar 

  13. Porter SJ, Somogyi AA, White JM (2000) Kinetics and inhibition of the formation of 6beta-natrexol from naltrexone in human liver cytosol. Br J Clin Pharmacol 50:465–471

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Gonzalez JP, Brogden RN (1988) Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35:192–213

    Article  CAS  PubMed  Google Scholar 

  15. Swift R, Davidson D, Rosen S, Fitz E, Camara P (1998) Naltrexone effects on diazepam intoxication and pharmacokinetics in humans. Psychopharmacology (Berl) 135:256–262

    Article  CAS  Google Scholar 

  16. Schroeder DH (1983) Metabolism and kinetics of bupropion. J Clin Psychiatry 44:79–81

    CAS  PubMed  Google Scholar 

  17. Findlay JW et al (1981) Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 21:127–135

    Article  CAS  PubMed  Google Scholar 

  18. Svensson CK (1997) Clinical pharmacokinetics of nicotine. Clin Pharmacokinet 12:30–40

    Article  Google Scholar 

  19. Yue J, Miksys S, Hoffmann E, Tyndale RF (2008) Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. J Psychiatry Neurosci 33:54–63

    PubMed  PubMed Central  Google Scholar 

  20. Wang Q et al (2015) Regulation of cerebral CYP2D6 alters tramadol metabolism in the brain: interactions of tramadol with propranolol and nicotine. Xenobiotica 45:335–344

    Google Scholar 

  21. Obach RS et al (2006) Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 34:121–130

    Article  CAS  PubMed  Google Scholar 

  22. Faessel HM et al (2010) A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet 49:799–816

    Article  CAS  PubMed  Google Scholar 

  23. Burstein AH et al (2007) Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study. J Clin Pharmacol 47:1421–1429

    Article  CAS  PubMed  Google Scholar 

  24. Faessel HM et al (2008) Lack of pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers. Eur J Clin Pharmacol 64:1101–1109

    Article  CAS  PubMed  Google Scholar 

  25. Talka R, Salminen O, Tuominen RK (2015) Methadone is a non-competitive antagonist at the α4b2 and α3* nicotinic acetylcholine receptors and an agonist at the α7 nicotinic acetylcholine receptor. Basic Clin Pharmacol Toxicol 116:321–328

    Google Scholar 

  26. Clemmey P, Brooner R, Chutuape MA, Kidorf M, Stitzer M (1997) Smoking habits and attitudes in a methadone maintenance treatment population. Drug Alcohol Depend 44:123–132

    Article  CAS  PubMed  Google Scholar 

  27. Story J, Stark MJ (1991) Treating cigarette smoking in methadone maintenance clients. J Psychoactive Drugs 23:203–215

    Article  CAS  PubMed  Google Scholar 

  28. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA (2006) ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 80:682–690

    Article  CAS  PubMed  Google Scholar 

  29. Barratt DT et al (2012) ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmgenomics Pers Med 5:53–62

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Levran O et al (2013) CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol 18:709–716

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Maany I, O’Brien CP, Woody G (1987) Interaction between thioridazine and naltrexone. Am J Psychiatry 144:966

    CAS  PubMed  Google Scholar 

  32. Haney M, Bisaga A, Foltin RW (2003) Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology (Berl) 166:77–85

    CAS  Google Scholar 

  33. Coller JK et al (2011) OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenet Genomics 21:902–905

    Article  CAS  PubMed  Google Scholar 

  34. Chamorro AJ et al (2012) Association of μ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systemative review and meta-analysis. Addict Biol 17:505–512

    Article  CAS  PubMed  Google Scholar 

  35. Garbutt JC et al (2014) Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction 109:1274–1284

    Article  PubMed  Google Scholar 

  36. Jonas DE et al (2014) Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis. Pharmacogenomics 15:1687–1700

    Article  CAS  PubMed  Google Scholar 

  37. Milton JC, Abdulla A (2007) Prolonged oro-facial dystonia in a 58 year old female following therapy with bupropion and St John’s Wort. Br J Clin Pharmacol 64:717–718

    Google Scholar 

  38. Lajtha A, Sershen H (2010) Nicotine: alcohol reward interactions. Neurochem Res 35:1248–1258

    Article  CAS  PubMed  Google Scholar 

  39. Levin ED, Rezvani AH (2007) Nicotinic interactions with antipsychotics drugs, models of schizophrenia and impacts on cognitive function. Biochem Pharmacol 74:1182–1191

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Ray R, Tyndale RF, Lerman C (2009) Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet 23:252–261

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Chen LS et al (2014) Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction 109:128–137

    Article  PubMed  PubMed Central  Google Scholar 

  42. Chen LS et al (2014) CHRNA5 variant predicts smoking cessation in patients with acute myocardial infarction. Nicotine Tob Res 16:1224–1231

    Article  PubMed  PubMed Central  Google Scholar 

  43. FDA USA (2014) Highlights of prescribing information CHANTIX® (varenicline). http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021928s033s034s037lbl.pdf

  44. FDA USA (2014) Campral (acamprosate calcium) tablets label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021431s013lbl.pdf

  45. FDA USA (2014) Highlights of prescribing information for Dolophine®. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/006134s035lbl.pdf

  46. FDA USA (2014) SUBUTEX (buprenorphine HCl sublingual tablets). http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM191529.pdf

  47. Teva Women’s Health Inc. (2014) ANTABUSE – disulfiram tablet. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ca0e1f-9641-48d5-9367-e5d1069e8680

  48. FDA USA (2014) Highlights of prescribing information VIVTROL®. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021897s015lbl.pdf

  49. FDA USA (2014) ZYBAN® (bupropion hydrochloride) sustained-release tablets. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020711s043lbl.pdf

Download references

Author information

Authors and Affiliations

  1. Discipline of Pharmacology, School of Medicine, The University of Adelaide, Adelaide, 5005, Australia

    Janet K. Coller BSc (Hon), PhD, GCert. Ed, Daniel T. Barratt PhD & Andrew A. Somogyi PhD

Authors
  1. Janet K. Coller BSc (Hon), PhD, GCert. Ed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel T. Barratt PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew A. Somogyi PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janet K. Coller BSc (Hon), PhD, GCert. Ed .

Editor information

Editors and Affiliations

  1. Univ. North Texas Sys, Col Pharmacy, Department of Pharmacotherapy, FORT WORTH, Texas, USA

    Michael W. Jann

  2. Department of Pharmacotherapy, Univ. North Texas Sys, Col Pharm, FORT WORTH, Texas, USA

    Scott R. Penzak

  3. Department of Pharmacotherapy, Univ. North Texas Sys, Col Pharm., FORT WORTH, Texas, USA

    Lawrence J. Cohen

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Coller, J.K., Barratt, D.T., Somogyi, A.A. (2016). Clinically Significant Interactions with Anti-addiction Agents. In: Jann, M., Penzak, S., Cohen, L. (eds) Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Adis, Cham. https://doi.org/10.1007/978-3-319-27883-4_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-27883-4_23

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-27881-0

  • Online ISBN: 978-3-319-27883-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation